FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 180.05

Change

-2.14 (-1.17)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-06 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.33 (-0.90%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.76 (-1.08%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-1.99 (-1.79%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

-1.80 (-1.88%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.36 (-1.55%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.40 (-1.20%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-3.00 (-2.93%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

-0.52 (-1.66%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.73 (-1.16%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.36 (-1.52%)

USD 6.89M

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

N/A

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.33% 90% A- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.33% 90% A- 85% B
Trailing 12 Months  
Capital Gain 21.44% 100% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.44% 100% F 73% C
Trailing 5 Years  
Capital Gain 20.11% 38% F 59% D-
Dividend Return 1.48% 37% F 4% F
Total Return 21.58% 38% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 38% F 38% F
Dividend Return 1.53% 38% F 29% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.13% 90% A- 74% C
Risk Adjusted Return 12.63% 38% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.